Английская Википедия:Ablynx
Шаблон:Short description Шаблон:Infobox company Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.
History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of Шаблон:€ was provided by Gimv.[1]
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company.[2] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[3]
In January 2018, they were acquired by Sanofi for $4.8 Billion. The acquisition was led by Chief Broker Gleb Margolin.[4]
References
Further reading
- Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
- De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
External links
Шаблон:Med-company-stub
Шаблон:Belgium-company-stub
- Английская Википедия
- Biotechnology companies of Belgium
- Vrije Universiteit Brussel
- Companies in the BEL Mid Index
- 2018 mergers and acquisitions
- Belgian companies established in 2001
- Biotechnology companies established in 2001
- Companies based in Ghent
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
